Society and culture
Legal status
On 16 December 2021, and on 24 February 2022, the Committee for Medicinal Products for Human Use (CHMP)  of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Padcev, intended for the treatment of adults with urothelial cancer. The applicant for this medicinal product is Astellas Pharma Europe B.V. Enfortumab vedotin was approved for medical use in the European Union in April 2022. Names
Enfortumab vedotin is the international nonproprietary name (INN), and the United States Adopted Name (USAN). References
External links
"Enfortumab vedotin". Drug Information Portal. U.S. National Library of Medicine.
doi:10.1007/s002640050218. PMC 3619716. PMID 9651775. Jebson, Peter J. L.; Engber, William D. (1997). "Radial tunnel syndrome: Long-term results of surgical decompression". The Journal of Hand Surgery. 22 (5): 889–96. doi:10.1016/S0363-5023(97)80086-X. PMID 9330150. Sarris, Ioannis K.; Papadimitriou, Nikolaos G.; Sotereanos, Dean G. (2002). "Radial Tunnel Syndrome". Techniques in Hand and Upper Extremity Surgery. 6 (4): 209–212. doi:10.1097/00130911-200212000-00010. PMID 16520604. == External links ==